Myeloproliferative syndromes and the associated risk of coronary artery disease

Thrombosis Research

Volumn 110, Issue 2-3, 2003, Pages 83-86

  Ganti, Apar Kishor ^a   Potti, Anil ^a   Koka, Vijay Kishore ^a   Pervez, Hassan ^a   Mehdi, Syed A ^b  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b Fargo VA Medical Center   (United States)

Author keywords

Coronary artery disease; Myeloproliferative syndromes; Polycythemia vera

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; STATISTICAL SIGNIFICANCE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0142258729     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00290-1     Document Type: Article

References (22)

1. Vardiman J.W. Chronic myelogenous leukemia and the myeloproliferative disorders. Knowles D. Neoplastic hematopathology. 1992;1405-1437 Williams and Wilkins, Baltimore.
2. Tarach J.S., Nowicka-Tarach B.M. Myeloproliferative disorders - neurological complications. Med. Sci. Monit. 6:2000;421-425.
3. Pearson T.C. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin. Oncol. 29(3 Suppl. 10):2002 (June);16-21.
4. Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann. Intern. Med. 123:1995;656-664.
5. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr. Opin. Hematol. 5:1998;327-331.
6. Chuncharunee S., Archararit N., Ungkanont A., Jootar S., Angchaisuksiri P., Bunyaratavej A.et al. Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis. J. Med. Assoc. Thai. 83(Suppl. 1):2000;S95-S100.
7. Joseph T., Hiltgen M., Gaulier A., Saudemont J.P. Myocardial infarction caused by thrombosis of the left coronary artery in a patient with thrombocythemia. Ann. Cardiol. Angeiol. 45:1996;581-584.
8. Brodmann S., Passweg J.R., Gratwohl A., Tichelli A., Skoda R.C. Myeloproliferative disorders: complications, survival and causes of death. Ann. Hematol. 79:2000;312-318.
9. Rosner B. Fundamentals of biostatistics. 4th ed. 1995;Duxbury Press, Belmont, CA.
10. Hachulla E., Rose C., Trillot N., Caulier-Leleu M.T., Pasturel-Michon U. What vascular events suggest a myeloproliferative disorder? J. Mal. Vasc. 25(5):2000;382-387.
11. Wehmeier A., Daum I., Jamin H., Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann. Hematol. 63:1991;101-106.
12. Avram S., Lupu A., Angelescu S., Olteanu N., Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J. Cell Mol. Med. 5:2001;79-87.
13. Harrison C.N., Donohoe S., Carr P., Dave M., Mackie I., Machin S.J. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb. Haemost. 87:2002;802-807.
14. Ambrus J.L., Ambrus C.M., Dembinsky W., Sykes D., Kulaylat M.N., Patel R.et al. Thromboembolic disease susceptibility related to red cell membrane fluidity in patients with polycythemia vera and effect of phlebotomies. J. Med. 30:1999;299-304.
15. Senno S.L., Pechet L. Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature. J. Thromb. Thrombolysis. 8:1999;105-112.
16. Mehta P., Mehta J., Ross M., Ostrowski N., Player D. Decreased platelet aggregation but increased thromboxane A2 generation in polycythemia vera. Arch. Intern. Med. 145:1985;1225-1227.
17. Kannel W.B., Vokonas P.S. Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women. Ann. Epidemiol. 2:1992;5-14.
18. Rossi C., Randi M.L., Zerbinati P., Rinaldi V., Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J. Intern. Med. 244:1998;49-53.
19. Cupples L.A., D'Agostino R.J. The Framingham study: an epidemiologic investigation of cardiovascular disease. Section 23. Some risk factors related to the annual incidence of cardiovascular disease and death, using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. 1987;US Department of Commerce, Springfield (VA).
20. Jantunen R., Juvonen E., Ikkala E., Oksanen K., Anttila P., Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann. Hematol. 80:2001;74-78.
21. Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 8:1990;556-562.
22. Randi M.L., Fabris F., Tison T., Barbone E., Rossi C., Girolami A. Prevalence of specific thrombotic accidents in patients with thrombocytosis. Haematologia. 25:1993;149-152.